国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
JOURNAL OF INTERNATIONAL ONCOLOGY
2010年
4期
276-278
,共3页
肿瘤%免疫耐受%吲哚胺-吡咯2,3-双加氧酶%CD4+CD25+T细胞
腫瘤%免疫耐受%吲哚胺-吡咯2,3-雙加氧酶%CD4+CD25+T細胞
종류%면역내수%신타알-필각2,3-쌍가양매%CD4+CD25+T세포
Neoplasms%Immune tolerance%Indoleamine-pyrrole 2,3-dioxygenase%CD4+ CD25+ T cells
调节性T细胞(Treg)介导的克隆抑制,是引起肿瘤免疫耐受的主要因素之一.而吲哚胺2,3双加氧酶(IDO)通过对Treg细胞的作用下调各系统肿瘤微环境中的免疫反应,从而诱导宿主免疫耐受的形成.IDO抑制剂1-MT将有望成为治疗肿瘤的新靶点.
調節性T細胞(Treg)介導的剋隆抑製,是引起腫瘤免疫耐受的主要因素之一.而吲哚胺2,3雙加氧酶(IDO)通過對Treg細胞的作用下調各繫統腫瘤微環境中的免疫反應,從而誘導宿主免疫耐受的形成.IDO抑製劑1-MT將有望成為治療腫瘤的新靶點.
조절성T세포(Treg)개도적극륭억제,시인기종류면역내수적주요인소지일.이신타알2,3쌍가양매(IDO)통과대Treg세포적작용하조각계통종류미배경중적면역반응,종이유도숙주면역내수적형성.IDO억제제1-MT장유망성위치료종류적신파점.
Clonal suppression induced by CD4+ CD25+ regulatory T cells is one of the principal factors to evoke the immune tolerance in tumor. Through the activation of CD4+ CD25+ regulatory T cells, the indoleamine 2,3-dioxygenase (IDO) reduces the immune response in tumor micro-environment of various systems , and induces the formation of host immune tolerance. IDO inhibitor 1-MT is expected to become a new target for cancer treatment.
